Companies /Healthcare
Abbvie Inc
NYSE: ABBV Drug Manufacturers - General
$291.31
▲ $3.07 (+1.07%) today
Markets closed · 1:13pm ET

AbbVie (ABBV) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
86%
EPS beat rate
+1.82%
Avg. EPS surprise
Consecutive EPS beats
ABBV vs Market · 30-day return after each reportABBVS&P 500
0%+4%+8%+12%−1.6%+6.7%Q1 25+12.1%+1.3%Q2 25+5.6%+0.3%Q3 25+4.8%−1.2%Q4 25+4.4%+6.6%Q1 26+3.6%+2.0%Q2 26
0%+4%+8%+12%Q1 25Q3 25Q1 26
ABBV EPS Trend · estimate vs actualEstimateActual
$0$2$4$2.40$2.46Q1 25$2.91$2.97Q2 25$1.78$1.86Q3 25$2.65$2.71Q4 25$2.67$2.65Q1 26$3.61$3.65Q2 26$3.78$3.82Q3 26
$0$2$4Q1 25Q3 25Q1 26Q3 26
ABBV Revenue Trend · estimate vs actualEstimateActual
$0$5.0B$10.0B$15.0B$12.9B$13.3BQ1 25$15.0B$15.4BQ2 25$15.6B$15.8BQ3 25$16.4B$16.6BQ4 25$14.7B$15.0BQ1 26$16.8B$17.0BQ2 26$17.3B$17.4BQ3 26
$0$5.0B$10.0B$15.0BQ1 25Q3 25Q1 26Q3 26

How Often Does AbbVie Beat Earnings Estimates?

AbbVie beat EPS estimates in 6 of its last 7 reported quarters, and has beaten 2 quarters in a row.

ABBV quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 Includes an unfavorable impact of $0.11 per share from acquired IPR&D and milestones expense ($216 million pre-tax, $205 million after-tax). GAAP diluted EPS of $2.37 additionally reflects intangible asset amortization ($1,669 million pre-tax), change in fair value of contingent consideration ($829 million pre-tax) and acquisition and integration costs ($408 million pre-tax, primarily Apogee Therapeutics). $3.82 est. $3.78 +1.09% $17.4B est. $17.3B +0.33%
Q2 2026 $3.65 est. $3.61 +1.15% $17.0B est. $16.8B +1.40%
Q1 2026 $2.65 est. $2.67 −0.66% $15.0B est. $14.7B +1.93%
Q4 2025 $2.71 est. $2.65 +2.16% $16.6B est. $16.4B +1.23%
Q3 2025 $1.86 est. $1.78 +4.23% $15.8B est. $15.6B +1.23%
Q2 2025 $2.97 est. $2.91 +2.14% $15.4B est. $15.0B +2.61%
Q1 2025 $2.46 est. $2.40 +2.62% $13.3B est. $12.9B +3.27%

Figures from SEC filings and company reports. Not investment advice.